Stock BVX BIVICTRIX THERAPEUTICS PLC
Add to a list
To use this feature you must be a member
Log inSign up

News BiVictriX Therapeutics plc

Equities

BVX

GB00BNXH3K91

Delayed London S.E.
Other stock markets
 02:59:59 2024-07-10 am EDT 		5-day change 1st Jan Change
13 GBX 0.00% Intraday chart for BiVictriX Therapeutics plc +4.00% +23.81%
Jun. 21 BiVictriX Therapeutics Plc Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jun. 13 EARNINGS AND TRADING: Dialight trades in line; Petards swings to loss AN

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BiVictriX Therapeutics Plc Reports Earnings Results for the Full Year Ended December 31, 2023
CI
EARNINGS AND TRADING: Dialight trades in line; Petards swings to loss
AN
BiVictriX Therapeutics' Leukemia Treatment Shows Favorable Safety Profile
MT
BiVictriX Therapeutics Plc Announces Compelling Safety Profile of BVX001 in Pre-Clinical Models Supports Progression to Clinic
CI
BiVictriX Wins Development Grant for Ovarian Cancer Drug Conjugate
MT
BiVictriX Therapeutics plc Receives Grants to Accelerate Solid Tumour Targeting ADC Pipeline from Innovate UK
CI
EARNINGS AND TRADING: CT UK High Income tops benchmark, ups dividend
AN
Bivictrix granted FDA orphan drug status for rare cancer treatment
AN
BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment
MT
Bivictrix Therapeutics plc Announces Resignation of Iain Ross from the Board
CI
Bivictrix selects final sequences for lead tumour programme
AN
BiVictriX Therapeutics plc Announces Pipeline Update on Lead Solid Tumour Programme, Bvx002
CI
BiVictriX patent boost; 4Global deal extended
AN
BiVictriX Obtains Japanese Patent for Acute Myeloid Leukemia Drug Conjugate
MT
Bivictrix Therapeutics Says Patent Granted In Japan Providing Further Broad Protection For BVX001
RE
Bivictrix says BVX001 increases survival rates by more than double
AN
BiVictriX Therapeutics' Blood Cancer Drug Delivers Extended Survival Rates in Trial
MT
Bivictrix Therapeutics PLC Extended Survival Rates Reported With Bvx001 In A Pre-Clinical Model Of Acute Myeloid Leukaemia
RE
BiVictriX Therapeutics appoints combined CFO/CBO to boost out-licensing efforts
AQ
Bivictrix hires new CFO as Alex Hughes steps down after seven months
AN
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BVX Stock
  4. News BiVictriX Therapeutics plc